Philina Lee
CIK 1845080 · Chief Commercial Officer · last filed 2025-07-21
Philina Lee is a Chief Commercial Officer who has filed 17 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for BPMC, was dated Jul 21, 2025. Across all open-market trades the lifetime net is −$5.3M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BPMC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
270 LONGWOOD ROAD SOUTH
HAMILTON, D0 L8P OA6
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp (BPMC) Delisted | Chief Commercial Officer | 0 | $129.46 | $0 | -$5.31M | 10 | 2025-07-21 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
Recent Filings
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-21 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −41,996 | $0 | EDGAR |
| 2025-03-07 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −3,733 | -$331.5K | EDGAR |
| 2025-03-04 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +11,000 | $0 | EDGAR |
| 2024-08-07 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$1.08M | EDGAR |
| 2024-08-05 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −46,436 | -$4.32M | EDGAR |
| 2024-06-04 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-03-15 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −6,276 | -$702.3K | EDGAR |
| 2024-03-13 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −8,023 | -$714.0K | EDGAR |
| 2024-03-11 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −2,934 | -$266.1K | EDGAR |
| 2024-03-06 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +12,500 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.